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Using Costs in Cost-Effectiveness Models for
Chronic Diseases
Lessons From Diabetes
Thomas J. Hoerger, PhD
Background: Cost-effectiveness models for chronic diseases fre-
quently require simulating the development of disease complications
over a long period. Model development often focuses on disease
progression, with less attention devoted to costs.
Objective: To identify key challenges in incorporating costs in
cost-effectiveness models for chronic diseases.
Research Design: We use our experience in developing and
applying a diabetes cost-effectiveness model to illustrate the
challenges in incorporating costs in cost-effectiveness models for
chronic diseases.
Results: Costs used in cost-effectiveness analyses for chronic dis-
eases are sometimes drawn from a variety of published sources with
little concern about consistency between sources or the underlying
functional form for costs. Identifying costs of complications in
chronic disease modeling often receives inadequate attention com-
pared to the time and effort devoted to modeling disease progres-
sion. Costs of averted complications typically cannot be estimated
during a trial, because these complications begin to accrue years
after the intervention. Complication costs may be estimated through
gross-costing, using an additive cost function with individual com-
plication costs derived from difference sources, or through cost
regressions that apply a multiplicative functional form using a single
data source. The choice between additive and multiplicative cost
functions may affect the cost-effectiveness ratios generated by the
model. Current guidelines do not provide much guidance on choos-
ing between the costing approaches.
Conclusions: Developing a set of standard cost estimates might
streamline the modeling process for chronic diseases, but standard-
ization will require careful attention to functional form and the
selection of appropriate data sets.
Key Words: cost-effectiveness, chronic disease, economic
analysis, diabetes
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This article identifies key challenges in incorporating costsin cost-effectiveness models for chronic diseases. Al-
though the challenges are similar across chronic diseases, we
focus on the case of diabetes and a particular diabetes
cost-effectiveness model to illustrate these challenges more
concretely. Our article lays the groundwork for later articles
in the volume that provide methods for overcoming these
challenges.
Several interrelated challenges must be overcome to
build and analyze cost-effectiveness models of chronic dis-
eases. First, the appropriate time horizon for chronic disease
is much longer than for acute conditions, because chronic
diseases progress gradually over time and because interven-
tions to slow progression may reduce complications years or
even decades after the intervention (and its costs) takes place.
This means that the model must carefully account for the
timing of costs and benefits, as with most models of preven-
tion. In addition, however, the long-time horizon means that
it can be costly and difficult to conduct lengthy clinical trials
that directly test whether chronic disease interventions im-
prove major health outcomes, such as mortality, heart attacks,
strokes, or other serious complications. When clinical trials
are infeasible, simulation models are an attractive alternative
for making predictions about the likely cost-effectiveness of
interventions for chronic disease.
The need to develop simulation models leads to a
second major challenge: chronic diseases are usually com-
plex, with progression depending on multiple risk factors and
producing several disease complications. As a result, devel-
opment of a cost-effectiveness model often focuses intently
on disease progression. Typically, great care is taken to
identify transition probabilities between disease states and to
link changes in intermediate health outcomes, such as blood
pressure or cholesterol, to long-term and more serious out-
comes, such as heart attacks or deaths. Adding interventions
to the model further intensifies the focus on disease progres-
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sion. Clinical trials may provide evidence of the interven-
tion’s effects on intermediate outcomes, but it is then up to
the disease progression model to simulate long-term outcomes.
If the model’s underlying assumptions about progression are
not convincing, the model’s conclusions about cost-effective-
ness will not be credible.
The intensive focus on disease progression leads to
the third challenge for cost-effectiveness modeling: often,
costs are treated almost as an afterthought in the modeling
process. By the time disease progression modeling is
complete, there may be relatively little time or budget left
to devote to cost collection. In other cases, economists may
be unavailable or allocated insufficient time to assess
options and consequences of assigning resources to disease
events or health care events.1
METHODS
In this article, we use our experience in developing and
applying the CDC-RTI diabetes cost-effectiveness model to
illustrate the challenges in incorporating costs in cost-effec-
tiveness models for chronic diseases. The CDC-RTI diabetes
cost-effectiveness model is a Markov simulation model of
disease progression and cost-effectiveness for type 2 diabetes.
Several other cost-effectiveness models exist for diabetes2–4;
our CDC-RTI model is fairly typical of the models that build
on Eastman’s original work in the area.5,6 To reflect the
chronic nature of diabetes, our model follows patients from
diagnosis to either death or age 95. The model simulates
development of diabetes-related complications on 3 micro-
vascular disease paths (nephropathy, which can culminate in
end-stage renal disease and death; neuropathy, which can
culminate in lower extremity amputation and death; and
retinopathy, which can culminate in blindness) and 2 macro-
vascular disease paths (coronary heart disease CHD and
stroke). The model also contains modules for diabetes screen-
ing and prediabetes. Model outcomes include disease com-
plications, deaths, costs, and quality-adjusted life years
(QALYs). The model has been used to: estimate the cost-
effectiveness of intensive glycemic control, intensified hyper-
tension control, and cholesterol reduction7; evaluate optimal
resource allocation across intervention programs8; assess
whether screening for diabetes is cost-effective9; show that
lifestyle modification is cost-effective in delaying or prevent-
ing diabetes among persons with prediabetes10; and estimate
the cost-effectiveness of screening for prediabetes.11 The
model focuses primarily on direct medical costs, although




Figure 1 provides a simplified illustration of the 5
disease paths within the model’s diagnosed diabetes module.
Ovals represent disease states, diamonds represent discrete
health events, and the Ps in rectangles represent the transition
probabilities that govern movements between states.
The point of showing this figure is not to provide a
detailed clinical explanation of diabetes progression. Rather,
it is to illustrate a common property of chronic disease
cost-effectiveness models: chronic diseases are complicated
and it takes great effort to create the disease progression
component of a cost-effectiveness model. The first step is to
specify the basic structure of disease progression. The next
step is to scour the clinical and epidemiological literature to
find all of the required transition probabilities for the model.
Once the structure has been specified and transition proba-
bilities and other parameters have been gathered, the third
step is to compile them in a simulation program, no small feat
in itself. After initial programming is complete, the final step
is to conduct a series of validation exercises to evaluate
whether the model predicts disease progression in a reason-
able and valid way. By the time all of these steps are
complete, building the disease progression component of a
cost-effectiveness model for chronic diseases may account
for a large share of the overall modeling effort.
The objective of cost-effectiveness modeling is to es-
timate the incremental costs and incremental effectiveness of
an intervention relative to a baseline treatment (eg, usual care
or doing nothing). Estimating the incremental effectiveness
of interventions for chronic diseases is especially challeng-
ing. Randomized clinical trials are generally regarded as
providing the best evidence on the potential effects of an
intervention on health outcomes. With chronic diseases, how-
ever, an intervention may not have a measurable impact on
long-term health outcomes such as heart attacks or death until
years or even decades after the intervention begins. There-
fore, clinical trials of interventions for chronic disease often
focus on the intervention’s effects on intermediate outcomes,
such as blood pressure, cholesterol, and—in the case of
diabetes—blood sugar levels (measured by hemoglobin A1c
levels). The intervention’s effects on long-term outcomes
must then be simulated by the disease progression model.
Figure 2 illustrates one of the diabetes model’s key
interventions and its links to long-term outcomes. The inten-
sive glycemic control intervention attempts to lower hemo-
globin A1c levels. Lower A1c levels are expected to slow the
development of early microvascular complications, which in
turn slows progression to end-stage complications, thereby
preventing death and increasing QALYs. The model’s param-
eters for glycemic control are based on the results of the
United Kingdom Prospective Diabetes Study, a landmark
clinical trial that followed newly diagnosed diabetes patients
for 10 years.12 The trial showed that the intensive control
intervention reduced A1c levels and early microvascular
complications relative to a standard control arm but could not
show a significant effect on end-stage complications be-
cause—despite the trial’s length—these were rare in both
arms of the trial. Therefore, we use the disease progression
model to simulate the long-term health effects. Intensive
glycemic control is only 1 of the 9 interventions included in
the diabetes model, and we take similar approaches in mod-
eling the other interventions. Because modeling the interven-
tion effects correctly is crucial for establishing the credibility
of a cost-effectiveness analysis, intervention modeling may
also account for a large share of the overall time spent on
building the model.
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With so much of the time in cost-effectiveness model-
ing devoted to disease progression and intervention effects,
costs may get relatively little attention. To save time for
analyzing the model and reporting results, developers often
simply find cost data in the literature from whatever source is
convenient and insert the costs in the model without looking
at them too carefully. As a result, costs may receive far less
FIGURE 1. Disease Paths. Ovals represent disease states, diamonds represent discrete health events, and pij represents the
transition probability from state i to state j. Note: micro, microalbuminuria; ESRD, end-stage renal disease; LEA, lower extrem-
ity amputation; CHD, coronary heart disease; CA/MI, cardiac arrest/myocardial infarction.
FIGURE 2. Intervention effects in the diabetes model. Note:
A1c, hemoglobin A1c.
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scrutiny and time in the modeling effort than disease progres-
sion, intervention effects, or analysis and reporting. The
individual costs may be derived from a variety of published
sources with little concern about consistency between sources
or the effects of the underlying functional form for costs.
In the case of our diabetes model, we used cost esti-
mates from more than a dozen published articles; most, if not
all, of these articles used different data sources. Our decision
to rely on so many sources was pragmatic: diabetes is
associated with a wide range of complications, and to derive
new estimates would almost require an original study for each
complication.
Measuring Costs
Chronic disease interventions typically have 2 major
cost consequences:
• Intervention costs: direct costs of implementing the inter-
vention (eg, tests, intervention materials, extra physician
visits, lifestyle counseling).
• Complication costs: if the intervention reduces subsequent
disease complications, future health costs may be averted.
The 2 types of costs may require different approaches
for cost collection.
Intervention costs can often be measured as a part of the
clinical trial that determines whether the intervention im-
proves intermediate health outcomes. The intervention costs
can be measured by microcosting (ie, carefully measuring the
incremental resources associated with the intervention and
multiplying by standard unit costs for each resource).
Clinical trials are too short for measuring the compli-
cation costs for many chronic diseases. Because of the long
potential delay between an intervention and major complica-
tions, the clinical trial period is usually too short to observe
statistically different rates of complications between the in-
tervention and control arms of the trial; therefore, statistically
significant differences in costs are also unlikely. Even pool-
ing complication costs across arms to determine a single
complication cost may be difficult because major complica-
tions may be too rare, and costs for individual complications
may be too variable. Consequently, complication costs often
must be estimated using other data sources and approaches.
One potential approach for estimating complication
costs is to cost out individual complications separately for
each disease-related complication. This approach, some-
times termed “gross-costing,”13 usually relies on secondary
data or estimates from previously published articles, with
costs for different complications often taken from different
sources. There may be an initial one-time cost estimate for
the year when a complication first occurs and an estimate of
annual recurring costs in subsequent years. For example, a
stroke may result in high hospitalization costs in the first year
and have recurring long-term costs in subsequent years. Our
diabetes cost-effectiveness model originally used this ap-
proach for complication costs. Table 1 shows the one-time
and annual costs for selected costs in the model.
Using multiple sources of data for gross-costing poten-
tially raises a number of issues. The sources may focus on
different populations, different health care systems, or differ-
ent periods, and different estimation techniques may be used
to generate each complication cost. This raises questions
about how representative the individual estimates are and
whether they can be combined meaningfully. Typically, only
a single mean value of the cost of a complication is used,
suppressing the fact that the cost of a complication can vary
widely between individuals. These issues are often ignored
in practice. However, most cost-effectiveness studies will
at least include 1-way sensitivity analyses to determine
whether individual cost parameters affect estimated cost-
effectiveness ratios. Probabilistic sensitivity analyses are
becoming increasingly common, and these analyses could
potentially explore variation in the cost of complications
across individuals.
An implicit assumption in gross-costing individual
costs separately is that the underlying cost function is additive
(so that the cost of having both a history of CHD and a history
of stroke equals the cost of having a history of CHD plus the
cost of having a history of stroke). This assumption permits
the use of separate sources of data for different complica-
tions. Costs that are not associated with the disease of interest
can also be ignored because they will cancel out in the
incremental cost comparison between an intervention and
control arm, assuming that the additive functional form is
correct and the intervention does not affect life expectancy.
An alternative approach for costing complications is to
formally estimate a cost regression that includes cost as the
dependent variable and dummy variables for key complica-
tions as explanatory variables. The regression approach to
costing generally involves more work than the additive cost-
ing approach. It requires a large data set, and the proper
functional form for the regression must be selected. As Basu
and Manning14 described later in this volume, some of the
regression equations are estimated with generalized linear
models using a log-link form:
E(y  y  0, X)  c  exp(X),
where y stands for costs or expenditures, c is a scale factor,
and X includes dummy variables for complications or con-
ditions. The exponential form is selected to account for the
skewed distribution of health care costs. Assuming there are
TABLE 1. Alternative Costing Approaches
Costs of Selected Diabetes Complications (Gross-Costing)
Complication One-Time Costs Annual Costs
Microalbuminuria $0 $0
Nephropathy $1201 $0
End-stage renal disease $0 $72,488
Peripheral neuropathy $357 $0




Myocardial infarction $16,534 $1118
Stroke (age 65–74) $21,613 $7599
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2 complications, X1 and X2, it becomes clear that complica-
tions have a multiplicative effect on costs:
E(y  y  0, X)  c  exp(  X11  X22),
 c  exp()  exp(X11)  exp(X22).
When complication 1 occurs (ie, X1  1), costs are
multiplied by exp(1). An often overlooked characteristic of
this functional form is that the incremental cost of a compli-
cation depends on an individual’s other complications. Thus,
there is no “single” cost of a complication, as in the first,
additive approach to costs. In addition, baseline costs in the
absence of complications do matter because these costs enter
the multiplicative equation. Finally, the multiplicative form
complicates efforts to calculate the share of costs attributable
to the complication.15
In one of the extensions of our diabetes cost-effective-
ness models, we used a regression-based cost function to
measure complication costs. Table 2 shows the corresponding
set of multipliers, which were derived from a study of
diabetes costs in a health maintenance organization; in the
study, c  1, and the natural log of costs was regressed on
complications and other variables.16 Using this regression, a
female patient with diabetes, microalbuminuria, and hyper-
tension and who used insulin would be estimated to have
costs of $4866 ( $1684  1.25  1.17  1.24  1.59). The
incremental cost of hypertension for this patient would be
$950. If the female patient had diabetes and hypertension but
did not have microalbuminuria or take insulin, her estimated
cost would be $2088 and the incremental cost of hypertension
would be $404.
The choice between additive and multiplicative models
will depend on both practical and theoretical issues. Practi-
cally, it may be quicker and cheaper to rely on existing cost
estimates from multiple sources, and these costs will usually
have to be combined in an additive framework because it
would be difficult to combine them multiplicatively. From a
theoretical standpoint, additive costing will be most appro-
priate when detailed data on both costs and diagnoses are
available and each cost can clearly be attributed to a single
diagnosis. Additive costing becomes more problematic if
there are economies of scope in medical care, so that it is
cheaper to treat a person’s hypertension and high cholesterol
in a single visit than in 2 separate visits. Alternatively, the
cost of treating a heart attack could be more expensive for a
person with both diabetes and hypertension than for a person
with only one or neither condition. Applying a multiplicative
cost function might be preferred from a theoretical perspec-
tive in these cases. It might also be preferred in the case of
patients treated by a vertically integrated delivery system,
whether the system delivers better economies of scope than
less integrated, horizontally organized systems.
An unresolved question is whether using the additive
cost approach or using the multiplicative cost function makes
a difference in a cost-effectiveness analysis. To investigate
this issue, we used our model to estimate the cost-effective-
ness of tightly controlling blood sugar levels, alternatively
using the additive and multiplicative cost functions (Table 3).
In this case, the additive cost function produces lower incre-
mental costs (incremental QALYs are the same in both
estimates) and therefore, a lower cost-effectiveness ratio than
the multiplicative cost function. Whether the difference be-
tween the cost-effectiveness ratios is important lies in the
eyes of the beholder. An optimist might note that the differ-
ence in incremental costs is relatively small and both cost-
effectiveness ratios are lower than the ratios for many health
care interventions that have been adopted. A pessimist might
focus on the $12,500/QALY difference between the cost-
effectiveness ratios and note that this difference could be
enough to affect a policymaker’s choice between accepting
and not accepting the intervention.
One other important characteristic of chronic disease
modeling is illustrated in Table 3. Although the difference in
incremental costs between the additive and multiplicative
cost functions is relatively small, the difference in cost-
effectiveness ratios is relatively large. This outcome occurs
because the denominator in the cost-effectiveness ratio, the
incremental QALYs produced by the intervention, is small
(0.145 QALYs). In cost-effectiveness analyses for primary
and secondary prevention of chronic diseases, small QALY
differences per patient are generally the rule, rather than the
exception, because the interventions are applied to a large
number of patients to prevent the development of rare com-
plications over a long period of time.17 This characteristic
underlines the importance of correctly measuring costs be-
cause a small change in incremental cost per patient can lead
to large changes in the cost-effectiveness ratio when the
incremental QALYs per patient are small.
Guidelines for Cost Measurement
Guidelines for cost-effectiveness analyses do not cur-
rently provide much guidance on the nuts and bolts of cost
measurement. Luce et al13 provide a comprehensive set of 25
recommendations for cost analysis in Chapter 6 of the treatise
on cost-effectiveness in health and medicine by Gold et al,
but only one of the recommendations focuses primarily on the
cost-measurement issues described in this article (Table 4).
Clearly, additional guidance would be useful, and, in fact, the
chapter closed by proposing that future research should de-








End-stage renal disease 10.53
History of stroke 1.30
Angina 1.73
History of myocardial infarction 1.90
Peripheral vascular disease 1.31
Hypertension 1.24
Baseline costs $1684
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velop a standard set of cost estimates that could be used in
cost-effectiveness analyses.
This proposal raises a number of questions. Can we
come up with a standardized list of complications or condi-
tions that is useful across a wide range of cost-effectiveness
analyses? Would the standard set include both one-time and
annual costs? What are the most appropriate data sources for
standardized cost estimates? Would the cost list be additive in
nature, or would it take the form of a multiplicative cost
function based on regressions? Finally, who would develop
the standardized costs? Many of these questions are ad-
dressed in detail in the articles later in this volume. Our
experience suggests that developers of cost-effectiveness
models would certainly welcome a standardized list of costs
that could be readily incorporated within cost-effectiveness
models. Developers would probably prefer a long list of
one-time and annual costs that would cover many conditions;
although it may be infeasible to generate the full list, costs for
common events such as heart attacks, strokes, and cancers
will be relevant for many conditions. Some models will
incorporate either additive or multiplicative regression-based
cost functions; the real question is which type of cost function
is appropriate.
CONCLUSIONS
This article illustrates some of the challenges in incor-
porating costs in cost-effectiveness models for chronic dis-
eases, using a diabetes cost-effectiveness model as a specific
example. For practical reasons, relatively little of the effort in
building cost-effectiveness models is devoted to cost mea-
surement. However, paying too little attention to costs can
threaten model validity and may lead to erroneous conclu-
sions about the cost-effectiveness of interventions. Interven-
tion costs can generally be estimated by microcosting as part
of clinical trials. However, measuring complication costs for
chronic diseases during a clinical trial is more difficult be-
cause complications are relatively rare and the associated
costs may be quite variable. Therefore, complication costs
will likely need to be estimated using gross-costing for
individual events or be derived from cost regressions. Devel-
oping a set of standard cost estimates might streamline the
modeling process and improve cost-effectiveness analyses,
but standardization will require careful attention to functional
form and the selection of appropriate data sets.
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Use societal perspective 1
What should be included in numerator 7
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1
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Total 25
Luce et al, 199613; recommendations grouped by author.
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